% | $
Quotes you view appear here for quick access.

Gilead Sciences Inc. Message Board

cd3313 3 posts  |  Last Activity: Sep 19, 2015 3:57 AM Member since: Mar 1, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • At 1:45 ET this afternoon, Gilead Sciences will present the following abstract for GS-5734 at ICAAC in San Diego:

    "Once-Daily Treatment With GS-5734 Initiated Three Days Post Viral Challenge Protects Rhesus Monkeys against Lethal Ebola Virus Disease (EVD)."

    When I first posted news of this Abstract in a previous message, no additional details were available. ICAAC has now unveiled the results and conclusions of the study on the conference's website. This is what was concluded:

    "GS-5734 is the first small molecule antiviral demonstrating robust therapeutic effect in monkey model of EVD. IV dosing initiated 3 days post infection was associated with 100% survival and marked suppression of EVD, supporting development of the compound as a potential treatment of EBOV infection in humans."

    I seem to recall awhile back, that Tekmira was tossed about here as one of the companies that "Gilead should buy" to boost the price of their stock...

    I guess Gilead's management team knew better.


    Sentiment: Strong Buy

  • Lots of interest in the $50, $55, and $60 strikes today.

    Long and Strong

    Sentiment: Strong Buy

  • Tomorrow morning, Gilead will be presenting at the Baird 2015 Healthcare Conference at 10:15 ET.

    On September 16, Gilead will be presenting at the Morgan Stanley Global Healthcare Conference at 1:05 ET.

    The 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) runs from September 17-21.

    Long and Strong

    Sentiment: Strong Buy

106.58+0.62(+0.59%)11:02 AMEST